<DOC>
	<DOCNO>NCT01768520</DOCNO>
	<brief_summary>This clinical trial plan prove Entelon tab . arm inferior Celebrex cap . arm term efficacy safety change K-WOMAC 's total score sum patient osteoarthritis knee .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Entelon Tab . 150mg Patients With Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1. gender,35 year ≤ age ≤ 75 year 2. patient diagnosis OA ( osteoarthritis ) knee within 3 month prior study participation , determine American College Rheumatology clinical radiographic criterion follow . 1. knee arthralgia 2. one case among 50 year morning stiffness le 30 min friction sound 3. osteophyte radiography 3 . Kellgren Lawrence Scale Grade II~III 4. total sum KWOMAC Scale 30 5. negative result pregnancy test urine screening period 6. woman childbearing age , medically reliable contraception menopause 7. patient give write consent agreement voluntarily participate clinical study 8. patient read understand write instruction 1. patient whose total sum KWOMAC visit 2 less visit 1 2. fibromyalgic , anserine bursitis , infectious arthritis , rheumatoid arthritis , ankylose spondylitis , gout pseudogout 3. knee OA secondary cause include major dysplastic congenital malformation , ochronosis , acromegaly , Hemochromatosis , Wilson 's disease primary osteochondromatosis 4. anatomical malformation , disease vertebra low extremity disease orthopedics disturb evaluation target joint 5. wound , inflammation avascular necrosis target joint arthroscopy within 6 month prior study participation 6. patient administration injectable hyaluronic acid target joint within 6 month prior study participation 7. severe ischaemic heart disease , peripheral artery disease and/or cerebrovascular disease , congestive heart failure , active bronchial asthma 8. medical history malignant tumor 9. active peptic ulcer , gastrointestinal tract bleed inflammatory bowel disease 10. hypersensitivity aspirin , celecoxib , corticosteroid , acetaminophen , sulfonamide derivative vitis vinifera intolerance fructose , glucose galactose 11. continuously ( 1 week ) oral intraarticular administration corticosteroid within 12 week prior study participation 12. pregnant lactate woman 13. patient experience participate clinical trial within 4 week prior study participation 14 . ALT , AST Serum Creatinine ≥ 2×UNL 15. drug administration diagnose alcoholic psychical disease 16. patient investigator judge improper participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>